Pinelopi Kouki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pinelopi Kouki has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Panagis Michael Lykoudis
University of Athens
2 shared publications - Anna Theodorou-Kanakari
Department of Anaesthesiology, General Hospital of Nikaia-Piraeus “Agios Panteleimon”, 18454 Athens, Greece
1 shared publication - Christos Iordanou
1st Surgical Department-Laparoscopic Unit, General Hospital of Piraeus Tzaneio, 18536 Piraeus, Greece
1 shared publication - Eleftheria Lelekaki
Intensive Care Unit, Naval Hospital of Athens, 11521 Athina, Greece
1 shared publication - Georgios Ayiomamitis
1st Surgical Department-Laparoscopic Unit, General Hospital of Piraeus Tzaneio, 18536 Piraeus, Greece
1 shared publication - Ioannis Karavolias
Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (19) , 3331
Artificial Intelligence and Large Language Models in Surgical Shared Decision-Making and Informed Consent: A Narrative Review
Background: Artificial intelligence (AI) and large language models (LLMs) may make surgical information easier to access and understand. However, these tools cannot replace the clinician’s role in shared decision-making or the requirements for valid informed consent. Methods: This narrative review follows the surgical patient pathway from diagnosis and explanation to option comparison, shared decision-making, and informed consent. It examines conventional digital tools, LLM-assisted communication, personalized prediction, direct consent studies, patient and professional perspectives and legal, ethical, and governance issues. A formal meta-analysis and study-level risk-of-bias assessment were not performed. Results: AI may support several stages of surgical care. Diagnostic and predictive systems can assist clinicians. LLMs can help explain approved information, prepare patients for consultation, and improve consent materials. Conventional interactive tools have the strongest evidence for better comprehension. Evidence for LLM-assisted consent is still based mainly on simulations and document analyses. Patient-facing use requires source control, privacy protection, and visible clinical oversight. AI cannot establish capacity, voluntariness, or final authorization. We propose a five-level framework in which safeguards increase with clinical influence. Conclusions: AI may support the patient’s path from diagnosis to an informed surgical choice when it uses approved information, serves a defined task, and remains under clinical oversight. Current evidence does not support autonomous AI-mediated consent or AI-directed treatment choice. The aim should be a better-informed, preference-sensitive decision, not an automated signature.
- 6 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (19) , 3331
Open AccessArtificial Intelligence and Large Language Models in Surgical Shared Decision-Making and Informed Consent: A Narrative Review
Background: Artificial intelligence (AI) and large language models (LLMs) may make surgical information easier to access and understand. However, these tools cannot replace the clinician’s role in shared decision-making or the requirements for valid informed consent. Methods: This narrative review follows the surgical patient pathway from diagnosis and explanation to option comparison, shared decision-making, and informed consent. It examines conventional digital tools, LLM-assisted communication, personalized prediction, direct consent studies, patient and professional perspectives and legal, ethical, and governance issues. A formal meta-analysis and study-level risk-of-bias assessment were not performed. Results: AI may support several stages of surgical care. Diagnostic and predictive systems can assist clinicians. LLMs can help explain approved information, prepare patients for consultation, and improve consent materials. Conventional interactive tools have the strongest evidence for better comprehension. Evidence for LLM-assisted consent is still based mainly on simulations and document analyses. Patient-facing use requires source control, privacy protection, and visible clinical oversight. AI cannot establish capacity, voluntariness, or final authorization. We propose a five-level framework in which safeguards increase with clinical influence. Conclusions: AI may support the patient’s path from diagnosis to an informed surgical choice when it uses approved information, serves a defined task, and remains under clinical oversight. Current evidence does not support autonomous AI-mediated consent or AI-directed treatment choice. The aim should be a better-informed, preference-sensitive decision, not an automated signature.
- Open Access
- 26 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4108
Intrathecal Nalbuphine Versus Other Opioids as Adjuvant to 0.5% Hyperbaric Bupivacaine in Caesarean Section: A Systematic Review and Meta-Analysis
Background/Objectives: Subarachnoid anaesthesia is widely preferred for caesarean delivery due to its rapid onset, reliability, and safety. The addition of adjuvants to intrathecal hyperbaric bupivacaine has been shown to enhance the quality of anaesthesia and prolong postoperative analgesia. Opioids are among the most frequently used intrathecal adjuvants; however, their administration is associated with adverse effects. Nalbuphine, a mixed opioid agonist–antagonist, may be a promising agent for obstetric use due to its favourable pharmacodynamic properties. This study aimed to systematically review and, where feasible, meta-analyse the evidence comparing nalbuphine with other intrathecal opioid adjuvants to hyperbaric bupivacaine 0.5% for caesarean section, with a primary focus on efficacy and safety. Methods: A systematic review and meta-analysis of controlled trials was conducted. Web of Science Core Collection, MEDLINE (PubMed), Scopus, the Library of Congress, and LISTA (EBSCO) were systematically searched to identify eligible studies. Pooled mean difference (MD) and risk ratio (RR) were calculated using random-effects model. Results: Ten studies encompassing 1095 parturients were included. Compared with fentanyl, intrathecal nalbuphine was associated with a modest prolongation of effective analgesia. However, this finding was accompanied by substantial heterogeneity and very low certainty of evidence. In contrast, morphine provided a longer duration of analgesia than nalbuphine. Overall, nalbuphine and fentanyl demonstrated comparable block characteristics, with only minimal and clinically insignificant differences in onset and duration. Importantly, nalbuphine was associated with fewer adverse effects, particularly shivering and PONV. Conclusions: Subarachnoid nalbuphine may serve as a potential alternative adjuvant to 0.5% hyperbaric bupivacaine in caesarean section anaesthesia. It may provide an analgesic efficacy comparable to fentanyl and, although less potent than morphine, it may demonstrate a more favourable safety profile.
- 26 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4108
Open AccessIntrathecal Nalbuphine Versus Other Opioids as Adjuvant to 0.5% Hyperbaric Bupivacaine in Caesarean Section: A Systematic Review and Meta-Analysis
Background/Objectives: Subarachnoid anaesthesia is widely preferred for caesarean delivery due to its rapid onset, reliability, and safety. The addition of adjuvants to intrathecal hyperbaric bupivacaine has been shown to enhance the quality of anaesthesia and prolong postoperative analgesia. Opioids are among the most frequently used intrathecal adjuvants; however, their administration is associated with adverse effects. Nalbuphine, a mixed opioid agonist–antagonist, may be a promising agent for obstetric use due to its favourable pharmacodynamic properties. This study aimed to systematically review and, where feasible, meta-analyse the evidence comparing nalbuphine with other intrathecal opioid adjuvants to hyperbaric bupivacaine 0.5% for caesarean section, with a primary focus on efficacy and safety. Methods: A systematic review and meta-analysis of controlled trials was conducted. Web of Science Core Collection, MEDLINE (PubMed), Scopus, the Library of Congress, and LISTA (EBSCO) were systematically searched to identify eligible studies. Pooled mean difference (MD) and risk ratio (RR) were calculated using random-effects model. Results: Ten studies encompassing 1095 parturients were included. Compared with fentanyl, intrathecal nalbuphine was associated with a modest prolongation of effective analgesia. However, this finding was accompanied by substantial heterogeneity and very low certainty of evidence. In contrast, morphine provided a longer duration of analgesia than nalbuphine. Overall, nalbuphine and fentanyl demonstrated comparable block characteristics, with only minimal and clinically insignificant differences in onset and duration. Importantly, nalbuphine was associated with fewer adverse effects, particularly shivering and PONV. Conclusions: Subarachnoid nalbuphine may serve as a potential alternative adjuvant to 0.5% hyperbaric bupivacaine in caesarean section anaesthesia. It may provide an analgesic efficacy comparable to fentanyl and, although less potent than morphine, it may demonstrate a more favourable safety profile.